CuraCell Oncology was featured in Labiotech’s coverage of NLS Days 2026, where next‑generation cell therapies and epigenetic innovation dominated the conversation among Nordic biotech leaders.

The meeting highlighted how the region’s oncology developers are pushing toward more precise, mechanism‑driven treatments. CuraCell’s progress in advancing personalised TIL therapies stood out within this landscape, with the company emphasising its focus on scalability, potency and faster turnaround times for solid‑tumour indications.

Across the conference, investors and industry experts pointed to a growing appetite for platforms capable of reshaping treatment paradigms rather than incrementally improving existing options. CuraCell’s approach — combining deep tumour‑targeting expertise with a commitment to manufacturability — reflects the type of innovation that continues to draw attention as Nordic biotech matures.

The article frames NLS Days 2026 as a snapshot of a sector shifting toward therapies that modify disease biology at its core. CuraCell’s work sits firmly within that momentum, underscoring its role in the region’s next wave of oncology breakthroughs.

Read the full article here.